CN113797222B - 氧胶囊、其制备方法与应用 - Google Patents
氧胶囊、其制备方法与应用 Download PDFInfo
- Publication number
- CN113797222B CN113797222B CN202111218716.5A CN202111218716A CN113797222B CN 113797222 B CN113797222 B CN 113797222B CN 202111218716 A CN202111218716 A CN 202111218716A CN 113797222 B CN113797222 B CN 113797222B
- Authority
- CN
- China
- Prior art keywords
- oxygen
- cocoa butter
- capsule
- butter liquid
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001301 oxygen Substances 0.000 title claims abstract description 181
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 181
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 122
- 239000002775 capsule Substances 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940110456 cocoa butter Drugs 0.000 claims abstract description 81
- 235000019868 cocoa butter Nutrition 0.000 claims abstract description 81
- 239000007788 liquid Substances 0.000 claims abstract description 67
- -1 oxygen ions Chemical class 0.000 claims abstract description 59
- 238000002156 mixing Methods 0.000 claims abstract description 22
- 238000011049 filling Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 9
- 239000007903 gelatin capsule Substances 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract description 10
- 201000005569 Gout Diseases 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 8
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 7
- 201000005917 gastric ulcer Diseases 0.000 abstract description 7
- 208000019901 Anxiety disease Diseases 0.000 abstract description 6
- 208000031662 Noncommunicable disease Diseases 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 5
- 230000036506 anxiety Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 206010039966 Senile dementia Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 201000007094 prostatitis Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000013507 chronic prostatitis Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003326 hypnotic agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000045 pyrolysis gas chromatography Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004227 thermal cracking Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002192 fatty aldehydes Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02W—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO WASTEWATER TREATMENT OR WASTE MANAGEMENT
- Y02W90/00—Enabling technologies or technologies with a potential or indirect contribution to greenhouse gas [GHG] emissions mitigation
- Y02W90/10—Bio-packaging, e.g. packing containers made from renewable resources or bio-plastics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Botany (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种氧胶囊及其制备方法与应用。本发明提供的氧胶囊的制备方法包括如下步骤:对脱臭可可脂进行三级分离,然后将负氧离子与经过三级分离后的脱臭可可脂液体进行混合处理,将离子氧存储在脱臭可可脂液体中,最后将经负氧离子处理过的脱臭可可脂液体灌装进胶囊壳中制成胶囊剂,从而制得氧胶囊。本发明提供的氧胶囊含氧量高,具有良好的补氧效果,对高血压、痛风、胃溃疡、焦虑症等多种慢性非传染性疾病以及系统性红斑狼疮、高原反应等均具有良好的预防、治疗或者辅助治疗的效果。
Description
技术领域
本发明属于医药技术领域,具体涉及一种氧胶囊及其制备方法与应用。
背景技术
人体细胞存活的三要素是水、营养(包括蛋白质、脂肪、碳水化合物以及矿物质与微量元素)和氧,轻度缺氧会使心跳加快,呼吸急促,重则危及人的生命,研究表明大脑组织细胞缺氧数分钟,便会出现不可逆转性死亡。绝大多数对人体有害的细菌、病毒和癌细胞都是在乏氧条件下更具活力,细胞缺氧是癌症、免疫和退化性疾病等各种疾病的一个显著因子。2019年的生理与医学诺贝尔奖被授予给三位研究人体氧感知机制的科学家,他们得出的结论是,缺氧诱导因子(HIF)是低氧相关基因的转录因子。HIF在细胞内积聚可诱导肿瘤血管的生长。因此,补氧对人体健康具有直接的促进作用,能有效提高人体的免疫力和自愈能力。
人体吸收氧的主要途径是通过呼吸,经由肺泡将分子氧(O2)与血红蛋白中的铁发生化合反应,转化成离子氧(O),通过血液循环系统,为全身各器官供氧。为挽救患者的生命,或者为亚健康的人养生养老的目的,人们不断探索各种人工补氧的方法,常用的有吸氧、插管、呼吸机、高压氧仓等。但这些方法都必须要通过人体肺部进行气体交换,当这条供氧通道出现障碍时,如发生急性肺炎、肺水肿和烧伤所致的吸入性损伤以及脑损伤引起的呼吸衰竭等疾病时,这些常用的呼吸道供氧方法效果不佳,患者的生命受到极大的危害。开通新的供氧通道,成为了医学界的研究热点和难点。
美国波士顿儿童医院的研究人员通过给气管被阻塞的兔子注射充氧微粒,使其在无呼吸状态下存活了15分钟,并保持正常的血压和心率。该充氧微粒是一种微粒胶囊,微粒胶囊内包含一层层由脂质生物分子组成的小球,每个小球周围都环绕着小气泡的氧气,这种充氧微粒主要以注射的方式注入血液中发挥作用(详见张巍巍.充氧微粒让呼吸停止的兔子存活15分钟[N].科技日报,2012-06-29(001).)。
为了克服呼吸机和高压氧舱等补氧方式的局限性,人们还发明了负氧离子发生装置,如中国专利CN108539592B公开的负氧离子发生装置。如果人体能够直接大量地吸收负氧离子发生装置所产生的负氧离子,就有机会突破目前供氧方法受限于人体肺泡转换能力的瓶颈。但是,氧离子(O)是极其不稳定的物质,在空气里,极易结合形成氧气(O2)和超氧(O3)。如果将负氧离子发生装置产生的负氧离子释放到空气里,在负氧离子释放口偏离几厘米的地方,就几乎测不到氧离子。如此,从负氧离子发生装置释放的氧离子,能被人体吸收的,也非常有限,在让人体吸收和有效利用足够高浓度、起到显著康复和疗效作用等方面都有很大的局限性。
发明内容
本发明的目的在于提供一种氧胶囊的制备方法,通过利用负氧离子发生装置产生的负氧离子对经过三级分离后的脱臭可可脂液体进行处理,将离子氧存储在脱臭可可脂液体中,然后将存储有离子氧的经负氧离子处理过的脱臭可可脂液体灌装进胶囊壳中制成胶囊剂,从而得到了本发明的氧胶囊。本发明提供的氧胶囊含氧量高,具有良好的补氧效果,具体表现为:对高血压、痛风、胃溃疡、焦虑症等多种慢性非传染性疾病以及系统性红斑狼疮、高原反应等均具有良好的防治或者辅助治疗的效果。
本发明的另一个目的在于提供氧胶囊在制备预防、治疗或辅助治疗慢性非传染性疾病、系统性红斑狼疮、高原反应中的至少一种的药品或保健食品中的应用。
根据本发明的一个方面,提供了一种氧胶囊的制备方法,包括如下步骤:
(1)将脱臭可可脂加热至50-70℃,然后冷却至25-28℃,在温度为25-28℃的条件下静置一定时间后过滤收集液体,得可可脂液体A;
(2)将可可脂液体A加热至30-33℃,然后冷却至19-21℃,在温度为19-21℃的条件下静置一定时间后过滤收集液体,得可可脂液体B;
(3)将可可脂液体B在温度为15-18℃的条件下搅拌一定时间后过滤收集液体,得可可脂液体C;
(4)将可可脂液体C置于混合装置中,然后将负氧离子输送至混合装置中与可可脂液体C混合,当负氧离子与可可脂液体C的混合达到饱和状态时,停止输送负氧离子,得经负氧离子处理过的脱臭可可脂液体,即氧胶囊内容物;
(5)将氧胶囊内容物灌装入胶囊壳中,即得氧胶囊。
与固态相比,液态的可可脂更易于与负氧离子混合以及发生化学反应,将负氧离子充分吸收并转化为氧离子存储在其中,且利用单一晶体结构或晶体结构趋于单一的可可脂液体制得的氧胶囊,其含氧量更高。可可脂具有多晶特性,且不同晶体形式的可可脂,其熔点不同,因此,利用可可脂的这一特性,可以对其进行多级分离获得具有单一晶体结构或基本具有单一晶体结构的可可脂。本发明对脱臭可可脂进行三级分离后得到的可可脂液体C,与负氧离子混合以及发生化学反应后,得到的经负氧离子处理过的脱臭可可脂液体(即氧胶囊内容物)的含氧量,按质量百分比计,可达10-30%。
在5℃或以下,氧胶囊内容物中所含的氧离子基本处于稳定状态。随着温度的升高,氧离子开始逐渐释放,温度越高,释放的速度越快。氧胶囊内容物中所含的氧离子在常温下处于半稳定状态,因此,本发明提供的氧胶囊需要放置在冰箱冷藏保存。
本发明提供的氧胶囊,服用时用水冲服即可。氧胶囊进入人体胃肠后,在人体体温的作用下,氧胶囊内容物中的氧离子开始释放,经胃肠黏膜吸收,进入循环系统,送达身体各个部位的器官。
本申请中,用于制备氧胶囊的胶囊壳可以为现有技术中公开的任意一种医药级或食品级胶囊壳,在一些实施方式中,胶囊壳可以选自食品级或医药级的明胶胶囊壳、糯米胶囊、玉米胶囊中的至少一种。
在一些实施方式中,胶囊壳可以为医药级明胶胶囊壳。
作为其中一种较优选的实施方式,氧胶囊的制备方法可以包括如下步骤:
(1)将脱臭可可脂加热至50-70℃,然后冷却至25-28℃,在温度为25-28℃的条件下静置5-7分钟后过滤收集液体,得可可脂液体A;
(2)将可可脂液体A加热至30-33℃,然后冷却至20℃,在温度为20℃的条件下静置6-8分钟后过滤收集液体,得可可脂液体B;
(3)将可可脂液体B在温度为15-18℃的条件下搅拌6-8分钟后过滤收集液体,得可可脂液体C;
(4)将可可脂液体C置于混合罐中,然后将负氧离子输送至混合罐中与可可脂液体C混合,当负氧离子与可可脂液体C的混合达到饱和状态时,停止输送负氧离子,得氧胶囊内容物;
(5)将氧胶囊内容物灌装入明胶胶囊壳中,即得氧胶囊。
本发明中,由于将负氧离子输送至混合罐中与可可脂液体C混合时,负氧离子会与可可脂液体C发生氧化反应,该氧化反应为放热反应,因此,会导致混合物和混合罐的温度升高,高于环境温度,因此,在往可可脂液体C中输送负氧离子的过程中,可以通过判断混合物和/或混合罐的温度是否重新降至与环境温度一致或基本一致来判断负氧离子与可可脂液体C的混合是否已达到饱和状态。
经初期的试用试验证明,本发明提供的氧胶囊可以有效用于治疗或者辅助治疗高血压、痛风、慢性前列腺炎、胃溃疡、焦虑症、老年痴呆等慢性非传染性疾病以及系统性红斑狼疮、高原反应等,因此,根据本发明的另一方面,提供了氧胶囊在制备预防、治疗或辅助治疗慢性非传染性疾病、系统性红斑狼疮、高原反应中的至少一种的药品或保健食品中的应用。
与现有技术相比,本发明的有益效果包括:
(1)本发明提供的氧胶囊的制备方法工艺简单,易于操作和实施,原料来源广;
(2)本发明提供的氧胶囊在制备过程中,原料仅用到脱臭可可脂和负氧离子两种成分以及食品级或医药级胶囊壳,成分安全,且氧胶囊携带和服用方便,用于治疗疾病或者辅助治疗疾病时,使用者的用药依从性高;
(3)本发明提供的氧胶囊补氧效果显著,对高血压、痛风、慢性前列腺炎、胃溃疡、焦虑症、老年痴呆等慢性非传染性疾病以及系统性红斑狼疮均具有显著的治疗或辅助治疗的效果。
附图说明
图1为本发明氧胶囊内容物的红外光谱图图;
图2为本发明氧胶囊内容物的热裂解气相色谱质谱联用(Py-GC/MS)总离子流图;
图3为本发明氧胶囊内容物的核磁共振氢谱图;
图4为本发明氧胶囊内容物的核磁共振碳谱图。
具体实施方式
下面结合实施方式对本发明作进一步详细的说明。实施例仅用于解释而不以任何方式限制本发明。如无特殊说明,实施例中所用原料和试剂为可以通过市售获得的常规产品;实施例中未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件。
实施例1氧胶囊的制备方法
包括如下步骤:
(1)将脱臭可可脂加热至温度为50℃左右,加热过程中不断搅拌使脱臭可可脂充分融化,然后冷却至28℃左右,在温度为25-28℃的条件下静置约5分钟后过滤收集液体,得可可脂液体A;
(2)将可可脂液体A边搅拌边加热至33℃左右,然后放入温度设置为20℃的恒温装置中静置6分钟后,过滤收集液体,得可可脂液体B;
(3)将可可脂液体B置于温度设置为15℃的恒温装置中,持续搅拌约6分钟后过滤收集液体,得可可脂液体C;
(4)将可可脂液体C置于密封式混合罐中,然后将负氧离子发生装置产生的负氧离子通过密闭的管道输送到混合罐中,使负氧离子与可可脂液体C混合,当混合罐的温度先升高,然后重新降至与环境温度一致或基本一致时,即,当负氧离子与可可脂液体C的混合达到饱和状态时,停止输送负氧离子,得氧胶囊内容物;
(5)将氧胶囊内容物灌装入医药级明胶胶囊壳中,即得氧胶囊。
实施例2氧胶囊的制备方法
包括如下步骤:
(1)将脱臭可可脂加热至温度为60℃左右,加热过程中不断搅拌使脱臭可可脂充分融化,然后冷却至25℃左右,放入温度设置为25℃的恒温装置中静置约7分钟后过滤收集液体,得可可脂液体A;
(2)将可可脂液体A边搅拌边加热至33℃左右,然后放入温度设置为20℃的恒温装置中静置8分钟后,过滤收集液体,得可可脂液体B;
(3)将可可脂液体B置于温度设置为16℃的恒温装置中,持续搅拌约8分钟后过滤收集液体,得可可脂液体C;
(4)将可可脂液体C置于密封式混合罐中,然后将负氧离子发生装置产生的负氧离子通过密闭的管道输送到混合罐中,使负氧离子与可可脂液体C混合,当混合罐的温度先升高,然后重新降至与环境温度一致或基本一致时,即,当负氧离子与可可脂液体C的混合达到饱和状态时,停止输送负氧离子,得氧胶囊内容物;
(5)将氧胶囊内容物灌装入医药级明胶胶囊壳中,即得氧胶囊。
实施例3氧胶囊的制备方法
包括如下步骤:
(1)将脱臭可可脂加热至温度为70℃左右,加热过程中不断搅拌使脱臭可可脂充分融化,然后冷却至26℃左右,放入温度设置为25℃的恒温装置中静置约7分钟后过滤收集液体,得可可脂液体A;
(2)将可可脂液体A边搅拌边加热至30℃左右,然后放入温度设置为20℃的恒温装置中静置8分钟后,过滤收集液体,得可可脂液体B;
(3)将可可脂液体B置于温度设置为15℃的恒温装置中,持续搅拌约8分钟后过滤收集液体,得可可脂液体C;
(4)将可可脂液体C置于密封式混合罐中,然后将负氧离子发生装置产生的负氧离子通过密闭的管道输送到混合罐中,使负氧离子与可可脂液体C混合,当混合罐的温度先升高,然后重新降至与环境温度一致或基本一致时,即,当负氧离子与可可脂液体C的混合达到饱和状态时,停止输送负氧离子,得氧胶囊内容物;
(5)将氧胶囊内容物灌装入医药级明胶胶囊壳中,即得氧胶囊。
一、氧胶囊成分检测
将本发明制得实施例2的氧胶囊内容物送至中科检测技术服务(广州)股份有限公司进行成分检测。检测过程中,当尝试将氧胶囊内容物放在红外灯下烘干时,氧胶囊内容物样品冒烟,由此也证明了本发明氧胶囊的内容物中含有氧离子且氧离子的状态不稳定,加热后氧离子会释放导致氧胶囊内容物样品在高温下发生燃烧。
用氧胶囊内容物原样进行了检测,本发明氧胶囊内容物的红外光谱图、热裂解气相色谱质谱联用(Py-GC/MS)总离子流图、核磁共振氢谱图、核磁共振碳谱图依次如图1-4所示。根据图谱分析,本发明提供的氧胶囊的内容物主要包括如下成分:脂肪酸甘油酯、脂肪酸异丙酯、脂肪酸、脂肪醛、脂肪酸缩水甘油酯。
由于氧胶囊内容物中的氧离子状态不稳定无法进行单独检测,因此,仅检测了氧胶囊内容物的含氧量。经检测,本发明提供的氧胶囊,其内容物的含氧量为24.268%。氧胶囊内容物中可能还包含有一些性质不稳定的中间产物,但由于其在检测条件下容易聚合成聚合物而无法准确分离和鉴定。
二、利用本发明氧胶囊治疗或辅助治疗疾病的典型案例
案例一、高血压
赵女士,79岁,定居于广州。高血压病史10年。服用本发明氧胶囊前,血压一般为140~160/110。如果临睡前高于140,第二天早晨起床需吃一片缬沙坦。2018年12月开始服用本发明氧胶囊,服用1个月后,临睡前血压再也没有高于140,缬沙坦也从那时起不再服用。现在平时血压一般在120~140/80。
案例二、高血压
王先生,59岁,定居于北京。高血压病史7年。服用本发明氧胶囊前,血压一般为140~150/90,每天早上吃降压药。2021年5月底开始口服氧胶囊,每日空腹两粒。2021年6月底停止服用降压药。目前血压一般维持在115/80。口服氧胶囊一周后,每日都有晨勃。
案例三、痛风
周先生,47岁,定居于广州,有5年痛风病史。服用本发明氧胶囊前,血尿酸630,2019年开始服用氧胶囊,三个月后,血尿酸降至522。此后没有采取任何医疗措施,2020年体检,发现血尿酸降至347;2021年7月体检,血尿酸保持在279。基本说明痛风得到根治。
案例四、痛风
王先生,46岁,定居于北京,有2年痛风病史。服用本发明氧胶囊前,血尿酸441,2021年6月开始服用氧胶囊,期间未服用任何其他药物,2021年8月底体检,血尿酸降至411,进入正常范围。
案例五、前列腺炎、老年痴呆
李先生,86岁,定居于上海,同时患有慢性前列腺炎和老年痴呆。前列腺炎严重到需要插导尿管才能排尿。2018年9月开始口服和肛塞氧胶囊,3个月后身体炎症消失,7个月后,通过彩超,医生决定可以拔掉尿管而不影响排尿。服用氧胶囊前、服用氧胶囊7个月后的彩超数据如下表1所示:
表1
横径 | 4.6cm | 4.3cm |
上下径 | 3.8cm | 3.7cm |
前后径 | 3.5cm | 3.0cm |
内腺大小 | 2.9×2.2cm | 2.8×2.0cm |
服用氧胶囊同时还使李先生的老年痴呆得到了改善。在服用氧胶囊之前,李先生已经不怎么认识自己的女儿,并且无法控制自己不要将嘴里的东西往外吐,嘴里只要有东西想吐,就会不管一切地吐出来。服用氧胶囊5个月之后,李先生逐渐有意识,不再随处吐痰。6个月后开始关心女儿是否穿暖衣服,并叮嘱女儿不要太累。9个月后在养老院的入院测试中(安全意识测试和蔬菜归类测试)被鉴定为非老年痴呆患者。
案例六、焦虑症
孙先生,60岁,定居于北美,高尔夫球教练。焦虑症病史5年,平时需要吃两粒安眠药才能入睡。学生比赛期间需要吃高达4粒才能入睡。稍有压力就会出现胃不舒服、头晕、焦躁不安等症状。2019年2月第一次服用两粒氧胶囊,当晚虽然还是吃2粒安眠药,但明显睡眠质量提高,第二天感觉精力充沛。一个月后,安眠药按照每周平均减少半粒的速度至完全停用。2019年4月至今,每天一粒氧胶囊,没有服用任何安眠药。即使有赛前压力,但胃不舒服、头晕、焦躁不安等症状不再出现。
案例七、系统性红斑狼疮
翟女士,52岁,定居于北美,家政服务业者。三十年前被诊断患有系统性红斑狼疮,在血液检查上,表现为白血球、血小板、淋巴细胞都大幅低于正常范围。接受过多种医药物疗法(包括激素药和中药)均无法治愈。服用激素药时,由于副作用巨大,导致对光的过敏,易疲劳,几乎每天都发烧,每天中午需要睡觉一两个小时,不然下午和晚上就十分疲累。2018年开始服用氧胶囊。服用氧胶囊之前(2017年6月5日),在美国做血液检查,几项系统性红斑狼疮相关血相指标结果如表2所示:
表2
检查项 | 结果 | 正常范围 |
白细胞WBC | 2.1 | 4.5-10.8 |
血小板PLT | 101 | 130-400 |
淋巴细胞LYM# | 0.5 | 1.2-3.4 |
在服用氧胶囊半年之后,就不再发烧,白天根本不用睡觉,整天都精力旺盛。服用两年多,在中国广州中山大学第一附属医院检查,几项系统性红斑狼疮相关血相指标检查结果如表3所示:
表3
检查项 | 结果 | 正常范围 |
白细胞WBC | 3.21 | 4-10 |
血小板PLT | 125 | 100-300 |
淋巴细胞LYM# | 1.0 | 1.0-3.3 |
其中白细胞接近正常,血小板和淋巴细胞已经正常。
案例八、胃溃疡
林先生,29岁,定居于广东,胃溃疡病史6年,必须按时吃饭,到点不吃饭,胃绞痛难忍。2020年3月起服用氧胶囊,每日两粒,共服用20日,期间未服用其他任何药物,后经医院检查,胃部溃疡伤口愈合,此后不再有胃痛发生。
以上所述的仅是本发明的一些实施方式。对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (3)
1.氧胶囊的制备方法,其特征在于,包括如下步骤:
(1)将脱臭可可脂加热至50-70℃,然后冷却至25-28℃,在温度为25-28℃的条件下静置5-7分钟后过滤收集液体,得可可脂液体A;
(2)将可可脂液体A加热至30-33℃,然后冷却至20℃,在温度为20℃的条件下静置6-8分钟后过滤收集液体,得可可脂液体B;
(3)将可可脂液体B在温度为15-18℃的条件下搅拌6-8分钟后过滤收集液体,得可可脂液体C;
(4)将可可脂液体C置于混合罐中,然后将负氧离子输送至混合罐中与可可脂液体C混合,当负氧离子与可可脂液体C的混合达到饱和状态时,停止输送负氧离子,得氧胶囊内容物;
(5)将氧胶囊内容物灌装入明胶胶囊壳中,即得氧胶囊;
按质量百分比计,所述氧胶囊内容物的含氧量为10-30%;
所述胶囊壳选自明胶胶囊壳、糯米胶囊壳、玉米胶囊壳中的至少一种。
2.根据权利要求1所述的制备方法,其特征在于,所述胶囊壳为明胶胶囊壳。
3.根据权利要求1-2任一项所述的制备方法制得的氧胶囊。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111218716.5A CN113797222B (zh) | 2021-10-19 | 2021-10-19 | 氧胶囊、其制备方法与应用 |
PCT/CN2022/115821 WO2023065833A1 (zh) | 2021-10-19 | 2022-08-30 | 氧胶囊、其制备方法与应用 |
US18/253,535 US20240000715A1 (en) | 2021-10-19 | 2022-08-30 | Oxygen capsule as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111218716.5A CN113797222B (zh) | 2021-10-19 | 2021-10-19 | 氧胶囊、其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113797222A CN113797222A (zh) | 2021-12-17 |
CN113797222B true CN113797222B (zh) | 2023-08-22 |
Family
ID=78898059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111218716.5A Active CN113797222B (zh) | 2021-10-19 | 2021-10-19 | 氧胶囊、其制备方法与应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240000715A1 (zh) |
CN (1) | CN113797222B (zh) |
WO (1) | WO2023065833A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113797222B (zh) * | 2021-10-19 | 2023-08-22 | 广州市生基科技有限公司 | 氧胶囊、其制备方法与应用 |
CN117462511B (zh) * | 2023-10-30 | 2024-04-09 | 广州市生基科技有限公司 | 一种提高补氧效果的氧胶囊及其制备方法 |
CN117357556B (zh) * | 2023-11-06 | 2024-04-19 | 广州市生基科技有限公司 | 一种高稳定性的氧胶囊的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008069078A (ja) * | 2006-09-12 | 2008-03-27 | Yukio Hasebe | 酸素入りソフトカプセル剤 |
KR20090024547A (ko) * | 2007-09-04 | 2009-03-09 | 김관식 | 산소 캡슐 제조 방법 및 제조 장치 |
CN102908334A (zh) * | 2012-11-15 | 2013-02-06 | 马克松 | 一种含氧胶囊 |
CN105977793A (zh) * | 2016-07-25 | 2016-09-28 | 龚剑豪 | 分离式负氧离子发生装置 |
CN111972664A (zh) * | 2020-08-10 | 2020-11-24 | 陈方红 | 一种保健胶囊 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960006935A (ko) * | 1994-08-30 | 1996-03-22 | 문정태 | 복합영양분말 음이온산소캡슐 |
DE102008037168A1 (de) * | 2008-08-06 | 2010-06-24 | Nowak, Götz, Prof. Dr. | Verwendung von Sauerstoff zur Behandlung von Erkrankungen der Schleimhaut des Magen-Darm-Kanals |
ES2842229T3 (es) * | 2014-12-19 | 2021-07-13 | Nestle Sa | Procedimiento de producción de un producto a base de grasa aireado |
CN113797222B (zh) * | 2021-10-19 | 2023-08-22 | 广州市生基科技有限公司 | 氧胶囊、其制备方法与应用 |
-
2021
- 2021-10-19 CN CN202111218716.5A patent/CN113797222B/zh active Active
-
2022
- 2022-08-30 WO PCT/CN2022/115821 patent/WO2023065833A1/zh active Application Filing
- 2022-08-30 US US18/253,535 patent/US20240000715A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008069078A (ja) * | 2006-09-12 | 2008-03-27 | Yukio Hasebe | 酸素入りソフトカプセル剤 |
KR20090024547A (ko) * | 2007-09-04 | 2009-03-09 | 김관식 | 산소 캡슐 제조 방법 및 제조 장치 |
CN102908334A (zh) * | 2012-11-15 | 2013-02-06 | 马克松 | 一种含氧胶囊 |
CN105977793A (zh) * | 2016-07-25 | 2016-09-28 | 龚剑豪 | 分离式负氧离子发生装置 |
CN111972664A (zh) * | 2020-08-10 | 2020-11-24 | 陈方红 | 一种保健胶囊 |
Non-Patent Citations (1)
Title |
---|
以乌桕脂为原料提取类可可脂;冯春发等;《化学工业与工程》;全文 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023065833A1 (zh) | 2023-04-27 |
CN113797222A (zh) | 2021-12-17 |
US20240000715A1 (en) | 2024-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113797222B (zh) | 氧胶囊、其制备方法与应用 | |
JP2005530737A (ja) | 壊死性腸炎の治療方法 | |
CN109646462A (zh) | 一种提取加工美洲大蠊的方法 | |
CN109498571B (zh) | 一种艾司奥美拉唑钠缓释微球及其制备方法 | |
US20220256873A1 (en) | Compositions, processes of production, sterilization, and health-promoting uses of lyophilized milk | |
CN108714208A (zh) | 组合物、其制备方法、应用和缓解压力、改善睡眠的产品 | |
WO2023005911A1 (zh) | 一种辅助治疗糖尿病的核苷酸组合物及其制备方法和应用 | |
CN109645492A (zh) | 一种具有预治过敏的儿童型组合物配方及其制备方法 | |
CN111329982B (zh) | 小柴胡颗粒联合磷酸氯喹的新应用 | |
CN109700830A (zh) | 一种口感好的治疗胃炎和消化性溃疡的药物及其制备方法 | |
CN109481459A (zh) | 一种复方电解质葡萄糖注射液及其制备方法 | |
CN106822762B (zh) | 一种质量稳定的风湿二十五味丸及其制备工艺 | |
CN117281846B (zh) | 一种用于提高耐缺氧能力的中药组合物及其制备方法与应用 | |
RU2706424C1 (ru) | Способ введения ксенона в организм человека при проведении ксенонотерапии | |
CN109999167A (zh) | 一种兼具调理情绪和减肥养生的中药组合物 | |
CN117357556B (zh) | 一种高稳定性的氧胶囊的制备方法 | |
RU2504395C1 (ru) | Способ профилактики бронхолегочной дисплазии у новорожденных с очень низкой и экстремально низкой массой тела при рождении | |
CN105362910B (zh) | 一种用于血虚体质的药食配方 | |
CN107233494A (zh) | 一种用于调节睡眠功能的中药配方 | |
CN104474421A (zh) | 一种治疗小儿夜惊啼哭的中药制剂及其制备方法 | |
CN112353886A (zh) | 一种治疗胃食管反流病肝胃郁热证的中药贴敷剂 | |
Antar et al. | Effect of Olfactory and Gustatory Stimulation on Premature Neonates' Feeding Progression and Sniffing Away Feeding Tube | |
CN111973563A (zh) | 一种鼠李糖脂冻干粉制剂及其制备方法和应用 | |
CN114796262A (zh) | 一种三原子氧化油胶囊制作方法 | |
WO1995011659A2 (fr) | Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 302, No. 3, Shansong 1st Street, Huangpu District, Guangzhou City, Guangdong Province, 510700 Applicant after: Guangzhou Shengji Technology Co.,Ltd. Address before: 510530 room 302-2, Keng Garden Mall, line 351, Xiangxue Avenue West, Luogang street, Huangpu District, Guangzhou, Guangdong G005 Applicant before: Guangzhou Shengji Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |